Novo Nordisk AS (NVO)
111.94
-0.01
(-0.01%)
USD |
NYSE |
Nov 01, 16:00
112.22
+0.28
(+0.25%)
After-Hours: 20:00
Novo Nordisk Max Drawdown (5Y): 23.65% for Oct. 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2024 | 23.65% |
| September 30, 2024 | 23.65% |
| August 31, 2024 | 23.65% |
| July 31, 2024 | 23.65% |
| June 30, 2024 | 23.65% |
| May 31, 2024 | 23.65% |
| April 30, 2024 | 23.65% |
| March 31, 2024 | 23.65% |
| February 29, 2024 | 23.65% |
| January 31, 2024 | 23.65% |
| December 31, 2023 | 23.65% |
| November 30, 2023 | 23.65% |
| October 31, 2023 | 23.65% |
| September 30, 2023 | 23.65% |
| August 31, 2023 | 23.81% |
| July 31, 2023 | 26.66% |
| June 30, 2023 | 26.66% |
| May 31, 2023 | 26.66% |
| April 30, 2023 | 26.66% |
| March 31, 2023 | 26.66% |
| February 28, 2023 | 26.66% |
| January 31, 2023 | 26.66% |
| December 31, 2022 | 26.66% |
| November 30, 2022 | 26.66% |
| October 31, 2022 | 26.66% |
| Date | Value |
|---|---|
| September 30, 2022 | 26.66% |
| August 31, 2022 | 26.66% |
| July 31, 2022 | 26.66% |
| June 30, 2022 | 26.66% |
| May 31, 2022 | 28.40% |
| April 30, 2022 | 28.40% |
| March 31, 2022 | 28.40% |
| February 28, 2022 | 32.26% |
| January 31, 2022 | 38.47% |
| December 31, 2021 | 43.74% |
| November 30, 2021 | 43.74% |
| October 31, 2021 | 43.74% |
| September 30, 2021 | 43.74% |
| August 31, 2021 | 46.14% |
| July 31, 2021 | 46.14% |
| June 30, 2021 | 46.14% |
| May 31, 2021 | 46.14% |
| April 30, 2021 | 46.14% |
| March 31, 2021 | 46.14% |
| February 28, 2021 | 46.14% |
| January 31, 2021 | 46.14% |
| December 31, 2020 | 46.14% |
| November 30, 2020 | 46.14% |
| October 31, 2020 | 46.14% |
| September 30, 2020 | 46.14% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
23.65%
Minimum
Sep 2023
46.14%
Maximum
Nov 2019
34.57%
Average
28.40%
Median
Mar 2022
Max Drawdown (5Y) Benchmarks
| Evaxion Biotech AS | -- |
| Amgen Inc | 24.86% |
| Viking Therapeutics Inc | 89.26% |
| Adaptimmune Therapeutics PLC | 96.45% |
| Genfit SA | 88.42% |